Introduction. Quick thrombolysis after stroke improved clinical outcomes. The study objective was to shorten door-to-needle time for thrombolysis. Methods. After identifying the sources of in-hospital delays, we developed a protocol with a parallel algorithm and recruited nurse practitioners into the acute stroke team. We applied the new protocol on stroke patients from October 2009 to Septembe...

OBJECTIVES To answer the question "In patients presenting with ST elevation acute myocardial infarction (STEMI) and no contraindication to thrombolysis, does the introduction of Tenecteplase reduce door to needle times?" METHODS Firstly, an observational study was performed to compare the time taken to prepare standard thrombolytic therapy with Tenecteplase. Secondly, door to needle times wer...

The aim of this study was to reduce the door-to-needle time in patients with ST-elevation acute myocardial infarction by setting up a chest pain service. We compared the door-to-needle time and outcomes at the end of first year of follow-up in patients who received fibrinolysis in the 2 years before implementation of the service (Group 1) and those who received fibrinolysis in the 2 years after...

The door-to-needle time is an important goal to reduce the time to treatment in intravenous thrombolysis. Objective Analyze if the inclusion of an exclusive thrombolytic bed reduces the door-to-needle time. Method One hundred and fifty patients admitted for neurological evaluation with ischemic stroke were separated in two groups: in the first, patients were admitted in the Emergency Room for i...

Neurology® 2012;79:1 IV human recombinant tissue plasminogen activator (rt-PA) is the best proven and most effective treatment for acute ischemic stroke. The benefits of rt-PA are highly dependent on the time elapsed since stroke symptoms.1 Accordingly, the Brain Attack Coalition recommends that the time from emergency room arrival to initiation of rt-PA (that is, the “door-toneedle” time) shou...

BACKGROUND AND PURPOSE In the United States, tissue plasminogen activator (tPA) was approved for treatment of acute ischemic stroke in 1996. Its use has only recently been approved in Canada. We sought to evaluate the safety, feasibility, and efficacy of treatment in a Canadian hospital setting. METHODS A combined retrospective and prospective review is presented of 46 consecutive patients tr...

BACKGROUND AND PURPOSE The benefits of intravenous tissue-type plasminogen activator (tPA) in acute ischemic stroke are time-dependent, and guidelines recommend a door-to-needle time of ≤60 minutes. However, fewer than one third of acute ischemic stroke patients who receive tPA are treated within guideline-recommended door-to-needle times. This article describes the design and rationale of TA...

OBJECTIVES Delays in parenteral antibiotic treatment may contribute to the high mortality in meningococcal disease. This study aimed to record "door to needle" time in children with meningococcal disease before and after the introduction of a specific teaching programme about the disease. METHODS "Door to needle" time in 33 children with meningococcal disease, admitted June 1995-December 1996...

INTRODUCTION It is well known that the efficacy of intravenous (i.v.) tissue plasminogen activator (tPA) is time-dependent when used to treat patients with acute ischemic strokes. AIM Our study examines the safety issue of giving IV tPA without complete blood count (CBC) resulted. MATERIALS AND METHODS This is a retrospective observational study by examining the database from Huashan Hospit...